Souhaitez-vous accéder aux communiqués récents ?

NON-REGULATORY PRESS RELEASE The Honorary Prize is awarded to an individual who has left a remarkable imprint and contributed with notable impact through their dedicated efforts and outstanding...

  All patients in cohort 2 who were alive after 2 years remain alive after 3 years Oslo, 19 June 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology...

Oslo, 08 June 2023, Board member Ketil Fjerdingen and primary insider in Ultimovacs ASA, has today through Langøya Invest AS bought 7,000 shares in the company at a price of NOK 79.5159 per share....

Oslo, 8 June 2023, Radforsk Investeringstiftelse, a closely associated party of Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 7,100 shares in the company...

The central independent review concluded that the NIPU study did not meet the primary endpoint of progression-free survival (PFS). However, a statistically significant improvement in PFS for patients...

Oslo, May 10, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its first quarter 2023 results today. First...

Oslo, 3 May 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter...

It is taking longer than estimated for the patients in the INITIUM study to experience disease progression, which is positive for patientsResults will be disclosed after cancer progression has been...

Oslo, 21 April 2023: On the basis of the approval by the General Meeting on 20 April 2023 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares...

Oslo, 20 April 2023: Ultimovacs ASA held its annual general meeting today 20 April 2023. All the matters on the agenda were approved. All board members were re-elected for a period of one year, and...